BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month
BX004 received FDA Fast Track designation in August
Part 1 data recently presented at the North American Cystic Fibrosis Conference (NACFC)
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.
“Thanks to the continued execution of our clinical team, we are now analyzing data from Part 2 of the Phase 1b/2a trial of BX004 and expect to announce the results later this month,” said Jonathan Solomon, Chief Executive Officer of BiomX. “I am also pleased to note that the positive data from Part 1 of our trial has been well received by physicians and patient advocacy groups at several prominent medical meetings, reflecting the need to develop innovative new therapies for combating these persistent and deadly lung infections. In addition, the U.S. Food and Drug Administration recently granted Fast Track designation for BX004, further underscoring the potential of this promising program.
“As a reminder, Part 2 of the trial is evaluating BX004 in a larger number of cystic fibrosis patients who are dosed twice a day and over a longer, 10-day treatment period compared to Part 1 of the trial. Part 2 of the trial will provide additional clinical data on safety and reduction in bacterial burden, along with other exploratory clinical endpoints, all of which will help us guide our clinical development strategy for the program. In light of the expected readout of the Part 2 data, we are forgoing our usual earnings call and will instead host a conference call and webcast following the release of the Part 2 data.”
Clinical Program Updates
Cystic Fibrosis (BX004)
Atopic Dermatitis (“AD”) (BX005)
Third Quarter 2023 Financial Results
Given the close proximity between the Company’s third quarter earnings report and the expected announcement of the Part 2 data from the Phase 1b/2a trial, BiomX management will forgo holding a call to review its third quarter 2023 earnings and will instead host a conference call and webcast following the release of the Part 2 data.
Source: BiomX Inc.
Keynote Presentation by Avant
CCaaS and MSPs: The Perfect Partnership